Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2009

View Archived Issues

First pediatric patient treated with Aptocine in neurofibromatosis study

Hana reaches enrollment target for phase II Marqibo trial in ALL

Zilver PTX Drug-Eluting Peripheral Stent receives approval in Europe

Antisoma and Bryan Oncor enter agreement for anticancer drug P-2045

Neurobiological Technologies terminates agreement with Merz and CMCC

Dynavax meets with EMEA for Heplisav HBV vaccine development strategy

FDA accepts to file Theratechnologies' tesamorelin NDA

Kuros reports data with KUR-212 in burn victims requiring mesh grafting

Labopharm submits response to FDA complete response letter for trazodone

Vedrop receives marketing authorization in the European Union

Tolerx amends phase III DEFEND protocol

Anadys reports viral load data for ANA-773 in hepatitis C patients

Avanir presents phase III study results for Zenvia

Anti-bovine thrombin 4A IgG cross-reacts with human thrombin and Recothrom

CB1/CB2 receptor antagonist THCV displays anticonvulsant activity in rat model of epilepsy

Novel antithrombotic agent S-35972 displays promising preclinical activity

Preclinical and early clinical data indicate that EP-42675 is a potent anticoagulant

O-3223 shows potency in preclinical models of inflammatory and neuropathic pain

PF-2341066 displays clinical activity in EML4-ALK translocation-positive NSCLC

Wyeth identifies liver X receptor modulators for the treatment of lipoprotein disorders

MEK kinase inhibitors for cancer treatment presented by Genentech

LG Life Sciences claims glucokinase activators for the treatment of diabetes

Merck & Co. describe c-Met kinase inhibitors for cancer treatment

Novel alpha2-adrenoceptor ligands in early development at Allergan

Novel tyrosine hydroxylase inducers discovered by French investigators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...